drugset / Trial / NCT05408663
A Phase 1 Study of EXT608 in Healthy Adults
Phase 1
Completed
24 enrolled
Extend Biosciences Inc.
Integrated Medical Development · collabNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabPharmaceutical Research Associates · collab
RandomizedSequentialDouble-blindTreatment
Summary
This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose safety and tolerability study of EXT608 in healthy subjects. There will be up to 6 sequential dose escalation cohorts of 4 participants. In each cohort 3 participants will receive EXT608 and 1 participant will receive placebo.
Timeline
- Start
- 2022-07-21
- Primary completion
- 2023-06-13
- Completion
- 2023-06-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EXT608 | Unknown | — | Subcutaneous |
Indications
No indication recorded.